查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930148

全球藥物基因組學市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Pharmacogenomics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 130 Pages | 商品交期: 請詢問到貨日

價格

藥物基因體學市場成長因素

全球藥物基因組學市場正經歷強勁成長，這主要得益於個人化醫療的快速發展和基因組學技術的進步。 2025年，該市場規模為34.6億美元，預計2026年將成長至37.9億美元，到2034年將達到80.9億美元，在預測期（2026-2034年）內複合年增長率（CAGR）為9.95%。北美地區在2025年佔市場主導地位，市場佔有率達39.47%，這得益於其先進的醫療基礎設施、精準醫療的早期應用以及有利的監管支持。

藥物基因組學研究患者的基因組成與其對藥物的反應之間的關係，使醫療保健提供者能夠優化藥物選擇和劑量，同時最大限度地減少副作用。對標靶治療日益增長的需求、慢性疾病負擔的加重以及基因組研究的大規模投資，都在顯著推動市場成長。

市場動態

市場驅動因素

藥物基因體學市場的一個關鍵驅動因素是對個人化醫療的重視。全球醫療保健系統正逐步從通用治療方法轉向基於基因的療法，以提高療效和安全性。下一代定序 (NGS) 和生物資訊學的進步顯著降低了定序成本和周轉時間，使藥物基因組學檢測更加普及。

此外，人口老化加劇以及癌症和心血管疾病等慢性疾病盛行率的上升，正在加速對基於精準醫療的治療決策的需求。 大型企業的策略性舉措也正在進一步推動市場擴張。例如，2025年6月，生物梅里埃宣布收購Day Zero Diagnostics，以加強其基於基因組定序的診斷產品組合。

市場限制因子

儘管技術不斷進步，但基因檢測和結果解讀缺乏標準化仍然是市場面臨的挑戰。不同實驗室的研究方法和報告框架不一致，限制了臨床醫生利用藥物基因組學數據進行治療決策的信心。此外，不同地區缺乏統一的報銷政策和監管指南也阻礙了其廣泛應用。

市場機會

人工智慧 (AI) 與藥物基因組學的融合帶來了巨大的成長機會。 AI驅動的平台可以分析大型基因組資料集，以識別基因-藥物交互作用、預測治療結果並優化給藥方案。對基於AI的精準醫療解決方案的投入增加有望釋放新的發展機會。

例如，2024 年 12 月，PGxAI, Inc. 從 InterSystems 獲得了 150 萬美元的融資，用於增強其專有的 AI 驅動的藥物基因組學演算法。

市場挑戰

限制市場擴張的一個關鍵挑戰是藥物基因組學資料與電子健康記錄 (EHR) 系統整合的難度。有限的互通性阻礙了在臨床診療點輕鬆利用基因資訊。儘管目前正在努力改善數據整合，但臨床決策支援工具普及程度的不均衡仍然是其廣泛應用的一大障礙。

藥物基因體學市場趨勢

影響市場的一個關鍵趨勢是藥物基因組學生物標記在臨床試驗和藥物開發中的應用日益廣泛。 FDA 和 EMA 等監管機構鼓勵將基因終點納入藥物標籤和伴隨診斷。這一趨勢正在推動藥物療效的提高、試驗失敗率的降低以及監管審批速度的加速。

例如，2024 年 8 月，Illumina 的綜合檢測產品 "TruSight Oncology" 獲得 FDA 批准，能夠分析 500 多個基因。這表明基因組學在以腫瘤學為重點的藥物基因組學領域的重要性日益凸顯。

細分市場分析

依服務劃分，由於對基因數據解讀和臨床報告的需求不斷增長，服務業在 2024 年佔市場主導地位。

依技術劃分，能夠同時分析多種基因突變的下一代定序 (NGS) 佔了相當大的市場佔有率。

依應用劃分，個人化醫療在個人化治療趨勢的推動下引領市場。

依疾病劃分，由於癌症具有很強的遺傳基礎以及對標靶癌症療法的需求不斷增長，腫瘤學在 2024 年佔了最大的市場佔有率。

依最終用戶劃分，學術研究機構在基因組學研究和政府資助的研究支持下，佔市場主導地位。

區域展望

北美預計將引領市場，2025年市場規模將達到13.6億美元，2026年將達到14.9億美元，主要得益於高額的醫療保健支出、強大的研究基礎設施和監管支持。

歐洲預計將佔較大佔有率，這主要歸功於合作基因組研究計劃和有利的醫療保健政策。

亞太地區預計將在預測期內實現最高的複合年增長率，這主要得益於中國、日本和印度等國家不斷增加的醫療保健投資和國家基因組計劃。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要公司新產品發布
  • 產業重大發展（併購、合作等）
  • 技術進步

第五章：全球藥物基因體學市場分析：洞察與預測（2021-2034）

  • 市場分析,洞察與預測：依類型
    • 產品
      • 耗材
      • 設備
    • 服務
  • 市場分析、洞察與預測：依技術
    • 次世代定序
    • 聚合酶鍊式反應 (PCR)
    • 微陣列
    • 原位雜交
    • 其他
  • 市場分析、洞察與預測：依應用
    • 個人化醫療
    • 藥物研發
    • 其他
  • 市場分析、洞察與預測：依疾病
    • 腫瘤學
    • 神經系統疾病
    • 心臟疾病
    • 其他
  • 市場分析、洞察與預測：依最終用戶用戶
    • 學術和研究機構
    • 製藥和生技公司
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美藥物基因體學市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第七章 亞太藥物基因體學市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第八章 拉丁美洲藥物基因體學市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第九章 中東與非洲藥物基因體學市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會（GCC）國家
    • 南亞國家非洲
    • 其他中東和非洲地區

第十章：競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Hoffmann-La Roche Ltd.
    • Illumina
    • Thermo Fisher Scientific
    • Qiagen
    • Agilent Technologies
    • Myriad Genetics
    • Admera Health, LLC
    • Bio-Rad Laboratories Inc.
    • Eurofins Scientific
    • Pathway Genomics
    • Other Prominent Players
Product Code: FBI106937

Growth Factors of pharmacogenomics Market

The global pharmacogenomics market is experiencing robust growth, driven by the rapid shift toward personalized medicine and advancements in genomic technologies. The market was valued at USD 3.46 billion in 2025 and is projected to grow to USD 3.79 billion in 2026, reaching USD 8.09 billion by 2034, registering a strong CAGR of 9.95% during the forecast period (2026-2034). North America dominated the market, accounting for a 39.47% share in 2025, supported by advanced healthcare infrastructure, early adoption of precision medicine, and favorable regulatory support.

Pharmacogenomics studies the relationship between a patient's genetic makeup and their response to medications, enabling healthcare providers to optimize drug selection and dosage while minimizing adverse effects. The increasing demand for targeted therapies, rising burden of chronic diseases, and extensive investments in genomic research are significantly fueling market growth.

Market Dynamics

Market Drivers

A major driver of the pharmacogenomics market is the strong emphasis on personalized medicine. Healthcare systems worldwide are increasingly moving away from generalized treatment approaches toward genetically guided therapies that improve efficacy and safety. Advancements in next-generation sequencing (NGS) and bioinformatics have significantly reduced sequencing costs and turnaround times, making pharmacogenomic testing more accessible.

Additionally, the growing geriatric population and increasing prevalence of chronic diseases such as cancer and cardiovascular disorders are accelerating the need for precision-based treatment decisions. Strategic initiatives by key players are further supporting market expansion. For instance, in June 2025, bioMerieux announced the acquisition of Day Zero Diagnostics to strengthen its genome sequencing-based diagnostics portfolio.

Market Restraints

Despite technological progress, the market faces challenges due to the lack of standardization in genetic testing and result interpretation. Variability in testing methodologies and reporting frameworks across laboratories creates inconsistencies, limiting clinicians' confidence in using pharmacogenomic data for treatment decisions. Additionally, the absence of uniform reimbursement policies and regulatory guidelines across regions continues to restrain widespread adoption.

Market Opportunities

The integration of artificial intelligence (AI) with pharmacogenomics presents a significant growth opportunity. AI-driven platforms can analyze large genomic datasets to identify gene-drug interactions, predict treatment outcomes, and optimize dosage regimens. Increasing investments in AI-based precision medicine solutions are expected to unlock new development opportunities.

For example, in December 2024, PGxAI raised USD 1.5 million in funding to enhance its proprietary AI-driven pharmacogenomics algorithms in collaboration with InterSystems.

Market Challenges

A major challenge limiting market scalability is the difficulty in integrating pharmacogenomic data with electronic health record (EHR) systems. Limited interoperability prevents genetic insights from being readily accessible at the point of care. Although initiatives are underway to improve data integration, inconsistent adoption of clinical decision support tools continues to hinder full-scale implementation.

Pharmacogenomics Market Trends

A key trend shaping the market is the increasing incorporation of pharmacogenomic biomarkers in clinical trials and drug development. Regulatory bodies such as the FDA and EMA are encouraging the integration of genetic endpoints in drug labeling and companion diagnostics. This trend is enhancing drug efficacy, reducing trial failures, and accelerating regulatory approvals.

For instance, in August 2024, Illumina received FDA approval for its TruSight Oncology comprehensive test, capable of analyzing over 500 genes, highlighting the growing importance of genomics in oncology-focused pharmacogenomics.

Segmentation Analysis

By type, the services segment dominated the market in 2024 due to rising demand for genetic data interpretation and clinical reporting.

By technique, next-generation sequencing (NGS) held a significant market share owing to its ability to analyze multiple genetic variants simultaneously.

By application, personalized medicine dominated the market, driven by the shift toward tailored therapies.

By disease, oncology accounted for the largest share in 2024 due to the strong genetic basis of cancer and growing demand for targeted cancer therapies.

By end-user, academic and research institutes led the market, supported by extensive genomic research and government-funded studies.

Regional Outlook

North America led the market with a valuation of USD 1.36 billion in 2025 and USD 1.49 billion in 2026, driven by high healthcare expenditure, strong research infrastructure, and regulatory support.

Europe held a significant share due to collaborative genomic initiatives and favorable healthcare policies.

Asia Pacific is expected to register the highest CAGR during the forecast period, supported by rising healthcare investments and national genomics programs in countries such as China, Japan, and India.

Competitive Landscape

The market is moderately consolidated, with key players such as Illumina, Thermo Fisher Scientific, Qiagen, and F. Hoffmann-La Roche Ltd. holding substantial market share. These companies are focusing on strategic collaborations, technology sharing, and portfolio expansion to strengthen their market presence.

Conclusion

The global pharmacogenomics market is set for significant expansion, driven by the accelerating adoption of personalized medicine, advancements in sequencing technologies, and growing integration of genomics into clinical decision-making. While challenges related to standardization, data integration, and reimbursement persist, emerging opportunities in AI-enabled pharmacogenomics and expanding applications in oncology and chronic disease management are expected to sustain market growth. With strong investments in research, supportive regulatory initiatives, and increasing clinical adoption, the pharmacogenomics market is poised to witness robust growth through 2034, reinforcing its critical role in the future of precision healthcare.

Segmentation By Type

  • Products
    • Consumables
    • Equipment
  • Services

By Technique

  • Next Generation Sequencing
  • Polymerase Chain Reaction
  • Microarrays
  • In-situ Hybridization
  • Others

By Application

  • Personalized Medicine
  • Drug Discovery
  • Others

By Disease

  • Oncology
  • Neurology
  • Cardiology
  • Others

By End-user

  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Others

By Region

  • North America (By Type, Technique, Application, Disease, End-user, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Technique, Application, Disease, End-user, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Type, Technique, Application, Disease, End-user, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Type, Technique, Application, Disease, End-user, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Technique, Application, Disease, End-user, and Country/Sub-region)
    • GCC
    • South Africa
    • Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. New Product Launches, By Key Players
  • 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
  • 4.3. Technological Advancements

5. Global Pharmacogenomics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Products
      • 5.1.1.1. Consumables
      • 5.1.1.2. Equipment
    • 5.1.2. Services
  • 5.2. Market Analysis, Insights and Forecast - By Technique
    • 5.2.1. Next Generation Sequencing
    • 5.2.2. Polymerase Chain Reaction
    • 5.2.3. Microarrays
    • 5.2.4. In-situ Hybridization
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Application
    • 5.3.1. Personalized Medicine
    • 5.3.2. Drug Discovery
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Disease
    • 5.4.1. Oncology
    • 5.4.2. Neurology
    • 5.4.3. Cardiology
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By End-user
    • 5.5.1. Academic and Research Institutes
    • 5.5.2. Pharmaceutical and Biotechnology Companies
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Pharmacogenomics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Products
      • 6.1.1.1. Consumables
      • 6.1.1.2. Equipment
    • 6.1.2. Services
  • 6.2. Market Analysis, Insights and Forecast - By Technique
    • 6.2.1. Next Generation Sequencing
    • 6.2.2. Polymerase Chain Reaction
    • 6.2.3. Microarrays
    • 6.2.4. In-situ Hybridization
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Application
    • 6.3.1. Personalized Medicine
    • 6.3.2. Drug Discovery
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Disease
    • 6.4.1. Oncology
    • 6.4.2. Neurology
    • 6.4.3. Cardiology
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By End-user
    • 6.5.1. Academic and Research Institutes
    • 6.5.2. Pharmaceutical and Biotechnology Companies
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 6.6.1. U.K.
    • 6.6.2. Germany
    • 6.6.3. France
    • 6.6.4. Spain
    • 6.6.5. Italy
    • 6.6.6. Scandinavia
    • 6.6.7. Rest of Europe

7. Asia Pacific Pharmacogenomics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Products
      • 7.1.1.1. Consumables
      • 7.1.1.2. Equipment
    • 7.1.2. Services
  • 7.2. Market Analysis, Insights and Forecast - By Technique
    • 7.2.1. Next Generation Sequencing
    • 7.2.2. Polymerase Chain Reaction
    • 7.2.3. Microarrays
    • 7.2.4. In-situ Hybridization
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Application
    • 7.3.1. Personalized Medicine
    • 7.3.2. Drug Discovery
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Disease
    • 7.4.1. Oncology
    • 7.4.2. Neurology
    • 7.4.3. Cardiology
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By End-user
    • 7.5.1. Academic and Research Institutes
    • 7.5.2. Pharmaceutical and Biotechnology Companies
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.6.1. Japan
    • 7.6.2. China
    • 7.6.3. India
    • 7.6.4. Australia
    • 7.6.5. Southeast Asia
    • 7.6.6. Rest of Asia Pacific

8. Latin America Pharmacogenomics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Products
      • 8.1.1.1. Consumables
      • 8.1.1.2. Equipment
    • 8.1.2. Services
  • 8.2. Market Analysis, Insights and Forecast - By Technique
    • 8.2.1. Next Generation Sequencing
    • 8.2.2. Polymerase Chain Reaction
    • 8.2.3. Microarrays
    • 8.2.4. In-situ Hybridization
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Application
    • 8.3.1. Personalized Medicine
    • 8.3.2. Drug Discovery
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Disease
    • 8.4.1. Oncology
    • 8.4.2. Neurology
    • 8.4.3. Cardiology
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By End-user
    • 8.5.1. Academic and Research Institutes
    • 8.5.2. Pharmaceutical and Biotechnology Companies
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.6.1. Brazil
    • 8.6.2. Mexico
    • 8.6.3. Rest of Latin America

9. Middle East & Africa Pharmacogenomics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Products
      • 9.1.1.1. Consumables
      • 9.1.1.2. Equipment
    • 9.1.2. Services
  • 9.2. Market Analysis, Insights and Forecast - By Technique
    • 9.2.1. Next Generation Sequencing
    • 9.2.2. Polymerase Chain Reaction
    • 9.2.3. Microarrays
    • 9.2.4. In-situ Hybridization
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Application
    • 9.3.1. Personalized Medicine
    • 9.3.2. Drug Discovery
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Disease
    • 9.4.1. Oncology
    • 9.4.2. Neurology
    • 9.4.3. Cardiology
    • 9.4.4. Others
  • 9.5. Market Analysis, Insights and Forecast - By End-user
    • 9.5.1. Academic and Research Institutes
    • 9.5.2. Pharmaceutical and Biotechnology Companies
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.6.1. GCC
    • 9.6.2. South Africa
    • 9.6.3. Rest of Middle East & Africa

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Hoffmann-La Roche Ltd.
      • 10.2.1.1. Overview
      • 10.2.1.2. Products
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. Illumina
      • 10.2.2.1. Overview
      • 10.2.2.2. Products
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Thermo Fisher Scientific
      • 10.2.3.1. Overview
      • 10.2.3.2. Products
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Qiagen
      • 10.2.4.1. Overview
      • 10.2.4.2. Products
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Agilent Technologies
      • 10.2.5.1. Overview
      • 10.2.5.2. Products
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Myriad Genetics
      • 10.2.6.1. Overview
      • 10.2.6.2. Products
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Admera Health, LLC
      • 10.2.7.1. Overview
      • 10.2.7.2. Products
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Bio-Rad Laboratories Inc.
      • 10.2.8.1. Overview
      • 10.2.8.2. Products
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Eurofins Scientific
      • 10.2.9.1. Overview
      • 10.2.9.2. Products
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)
    • 10.2.10. Pathway Genomics
      • 10.2.10.1. Overview
      • 10.2.10.2. Products
      • 10.2.10.3. SWOT Analysis
      • 10.2.10.4. Recent Developments
      • 10.2.10.5. Strategies
      • 10.2.10.6. Financials (Based on Availability)
    • 10.2.11. Other Prominent Players
      • 10.2.11.1. Overview
      • 10.2.11.2. Products
      • 10.2.11.3. SWOT Analysis
      • 10.2.11.4. Recent Developments
      • 10.2.11.5. Strategies
      • 10.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Pharmacogenomics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Pharmacogenomics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 3: Global Pharmacogenomics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 4: Global Pharmacogenomics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 5: Global Pharmacogenomics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 6: Global Pharmacogenomics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 7: Global Pharmacogenomics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 8: North America Pharmacogenomics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 9: North America Pharmacogenomics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 10: North America Pharmacogenomics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 11: North America Pharmacogenomics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 12: North America Pharmacogenomics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 13: North America Pharmacogenomics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 14: North America Pharmacogenomics Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 15: Europe Pharmacogenomics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 16: Europe Pharmacogenomics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 17: Europe Pharmacogenomics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 18: Europe Pharmacogenomics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 19: Europe Pharmacogenomics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 20: Europe Pharmacogenomics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 21: Europe Pharmacogenomics Market Revenue (USD billion) Forecast, by Country/Sub-region, 2021-2034
  • Table 22: Asia Pacific Pharmacogenomics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 23: Asia Pacific Pharmacogenomics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 24: Asia Pacific Pharmacogenomics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 25: Asia Pacific Pharmacogenomics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 26: Asia Pacific Pharmacogenomics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 27: Asia Pacific Pharmacogenomics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 28: Asia Pacific Pharmacogenomics Market Revenue (USD billion) Forecast, by Country/Sub-region, 2021-2034
  • Table 29: Latin America Pharmacogenomics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 30: Latin America Pharmacogenomics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 31: Latin America Pharmacogenomics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 32: Latin America Pharmacogenomics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 33: Latin America Pharmacogenomics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 34: Latin America Pharmacogenomics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 35: Latin America Pharmacogenomics Market Revenue (USD billion) Forecast, by Country/Sub-region, 2021-2034
  • Table 36: Middle East and Africa Pharmacogenomics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 37: Middle East and Africa Pharmacogenomics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 38: Middle East and Africa Pharmacogenomics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 39: Middle East and Africa Pharmacogenomics Market Revenue (USD billion) Forecast, by Application, 2021-2034
  • Table 40: Middle East and Africa Pharmacogenomics Market Revenue (USD billion) Forecast, by Disease, 2021-2034
  • Table 41: Middle East and Africa Pharmacogenomics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 42: Middle East and Africa Pharmacogenomics Market Revenue (USD billion) Forecast, by Country/Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Pharmacogenomics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Pharmacogenomics Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Pharmacogenomics Market Value Share (%), by Type, 2025
  • Figure 4: Global Pharmacogenomics Market Value Share (%), by Technique, 2025 & 2034
  • Figure 5: Global Pharmacogenomics Market Value Share (%), by Technique, 2025
  • Figure 6: Global Pharmacogenomics Market Value Share (%), by Application, 2025 & 2034
  • Figure 7: Global Pharmacogenomics Market Value Share (%), by Application, 2025
  • Figure 8: Global Pharmacogenomics Market Value Share (%), by Disease, 2025 & 2034
  • Figure 9: Global Pharmacogenomics Market Value Share (%), by Disease, 2025
  • Figure 10: Global Pharmacogenomics Market Value Share (%), by End-user, 2025 & 2034
  • Figure 11: Global Pharmacogenomics Market Value Share (%), by End-user, 2025
  • Figure 12: Global Pharmacogenomics Market Value Share (%), by Region, 2025 & 2034
  • Figure 13: Global Pharmacogenomics Market Value Share (%), by Region, 2025
  • Figure 14: North America Pharmacogenomics Market Value Share (%), by Type, 2025 & 2034
  • Figure 15: North America Pharmacogenomics Market Value Share (%), by Type, 2025
  • Figure 16: North America Pharmacogenomics Market Value Share (%), by Technique, 2025 & 2034
  • Figure 17: North America Pharmacogenomics Market Value Share (%), by Technique, 2025
  • Figure 18: North America Pharmacogenomics Market Value Share (%), by Application, 2025 & 2034
  • Figure 19: North America Pharmacogenomics Market Value Share (%), by Application, 2025
  • Figure 20: North America Pharmacogenomics Market Value Share (%), by Disease, 2025 & 2034
  • Figure 21: North America Pharmacogenomics Market Value Share (%), by Disease, 2025
  • Figure 22: North America Pharmacogenomics Market Value Share (%), by End-user, 2025 & 2034
  • Figure 23: North America Pharmacogenomics Market Value Share (%), by End-user, 2025
  • Figure 24: North America Pharmacogenomics Market Value Share (%), by Country, 2025 & 2034
  • Figure 25: North America Pharmacogenomics Market Value Share (%), by Country, 2025
  • Figure 26: Europe Pharmacogenomics Market Value Share (%), by Type, 2025 & 2034
  • Figure 27: Europe Pharmacogenomics Market Value Share (%), by Type, 2025
  • Figure 28: Europe Pharmacogenomics Market Value Share (%), by Technique, 2025 & 2034
  • Figure 29: Europe Pharmacogenomics Market Value Share (%), by Technique, 2025
  • Figure 30: Europe Pharmacogenomics Market Value Share (%), by Application, 2025 & 2034
  • Figure 31: Europe Pharmacogenomics Market Value Share (%), by Application, 2025
  • Figure 32: Europe Pharmacogenomics Market Value Share (%), by Disease, 2025 & 2034
  • Figure 33: Europe Pharmacogenomics Market Value Share (%), by Disease, 2025
  • Figure 34: Europe Pharmacogenomics Market Value Share (%), by End-user, 2025 & 2034
  • Figure 35: Europe Pharmacogenomics Market Value Share (%), by End-user, 2025
  • Figure 36: Europe Pharmacogenomics Market Value Share (%), by Country, 2025 & 2034
  • Figure 37: Europe Pharmacogenomics Market Value Share (%), by Country, 2025
  • Figure 38: Asia Pacific Pharmacogenomics Market Value Share (%), by Type, 2025 & 2034
  • Figure 39: Asia Pacific Pharmacogenomics Market Value Share (%), by Type, 2025
  • Figure 40: Asia Pacific Pharmacogenomics Market Value Share (%), by Technique, 2025 & 2034
  • Figure 41: Asia Pacific Pharmacogenomics Market Value Share (%), by Technique, 2025
  • Figure 42: Asia Pacific Pharmacogenomics Market Value Share (%), by Application, 2025 & 2034
  • Figure 43: Asia Pacific Pharmacogenomics Market Value Share (%), by Application, 2025
  • Figure 44: Asia Pacific Pharmacogenomics Market Value Share (%), by Disease, 2025 & 2034
  • Figure 45: Asia Pacific Pharmacogenomics Market Value Share (%), by Disease, 2025
  • Figure 46: Asia Pacific Pharmacogenomics Market Value Share (%), by End-user, 2025 & 2034
  • Figure 47: Asia Pacific Pharmacogenomics Market Value Share (%), by End-user, 2025
  • Figure 48: Asia Pacific Pharmacogenomics Market Value Share (%), by Country, 2025 & 2034
  • Figure 49: Asia Pacific Pharmacogenomics Market Value Share (%), by Country, 2025
  • Figure 50: Latin America Pharmacogenomics Market Value Share (%), by Type, 2025 & 2034
  • Figure 51: Latin America Pharmacogenomics Market Value Share (%), by Type, 2025
  • Figure 52: Latin America Pharmacogenomics Market Value Share (%), by Technique, 2025 & 2034
  • Figure 53: Latin America Pharmacogenomics Market Value Share (%), by Technique, 2025
  • Figure 54: Latin America Pharmacogenomics Market Value Share (%), by Application, 2025 & 2034
  • Figure 55: Latin America Pharmacogenomics Market Value Share (%), by Application, 2025
  • Figure 56: Latin America Pharmacogenomics Market Value Share (%), by Disease, 2025 & 2034
  • Figure 57: Latin America Pharmacogenomics Market Value Share (%), by Disease, 2025
  • Figure 58: Latin America Pharmacogenomics Market Value Share (%), by End-user, 2025 & 2034
  • Figure 59: Latin America Pharmacogenomics Market Value Share (%), by End-user, 2025
  • Figure 60: Latin America Pharmacogenomics Market Value Share (%), by Country, 2025 & 2034
  • Figure 61: Latin America Pharmacogenomics Market Value Share (%), by Country, 2025
  • Figure 62: Middle East and Africa Pharmacogenomics Market Value Share (%), by Type, 2025 & 2034
  • Figure 63: Middle East and Africa Pharmacogenomics Market Value Share (%), by Type, 2025
  • Figure 64: Middle East and Africa Pharmacogenomics Market Value Share (%), by Technique, 2025 & 2034
  • Figure 65: Middle East and Africa Pharmacogenomics Market Value Share (%), by Technique, 2025
  • Figure 66: Middle East and Africa Pharmacogenomics Market Value Share (%), by Application, 2025 & 2034
  • Figure 67: Middle East and Africa Pharmacogenomics Market Value Share (%), by Application, 2025
  • Figure 68: Middle East and Africa Pharmacogenomics Market Value Share (%), by Disease, 2025 & 2034
  • Figure 69: Middle East and Africa Pharmacogenomics Market Value Share (%), by Disease, 2025
  • Figure 70: Middle East and Africa Pharmacogenomics Market Value Share (%), by End-user, 2025 & 2034
  • Figure 71: Middle East and Africa Pharmacogenomics Market Value Share (%), by End-user, 2025
  • Figure 72: Middle East and Africa Pharmacogenomics Market Value Share (%), by Country, 2025 & 2034
  • Figure 73: Middle East and Africa Pharmacogenomics Market Value Share (%), by Country, 2025
  • Figure 74: Global Pharmacogenomics Market Share (%), By Company, 2025